ANIK (Anika) רווחיות מכירות לפי רווח גולמי

Anika Therapeutics operates in a protected sector that remains independent of global macroeconomic fluctuations. Business growth is accelerating through the acquisition of sports medicine brands and partnerships with orthopedic centers. This chart provided by GURU.Markets shows the gross profit margin holding at 63.40, confirming the sales efficiency of implants and hyaluronic products for cartilage restoration.
פילוחי מדדים מקיפים ואנליטיקה עבור Anika (ANIK)

For the non-cyclical business of Anika Therapeutics (ANIK), the gross profit margin serves as an indicator of stable demand for joint restoration products amid an aging population. This metric measures the remaining funds after covering direct production costs, where high profitability protects capital from inflationary shocks, while rising costs of goods sold signal a risk of operational compression and a decline in bottom-line profit.